This post was originally published on this site Amgen’s investigational therapy AMG 212 (pasotuxizumab) is safe, and showing therapeutic activity against metastatic castration-resistant prostate cancer (mCRPC) in a Phase 1 clinical trial, data show. This is the first study suggesting that Amgen’s BiTE immunotherapy, designed to bring together patients’ immune T-cells and cancer cells, “can…
This post was originally published on this site Europe’s umbrella organization for 800 rare disease associations has developed a sweeping initiative to help the continent’s 30 million rare disease patients and their caregivers learn about their conditions, find assistance and receive treatment. Eurordis-Rare Diseases Europe hopes to improve the current piecemeal treatment and support program with…
This post was originally published on this site Aliqopa (copanlisib) has been granted Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with relapsed marginal zone lymphoma (MZL) who have received at least two prior therapies. The designation is intended to accelerate the development and review of…
This post was originally published on this site The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Arvinas‘ lead protein degrader ARV-110 to treat patients with metastatic castration-resistant prostate cancer (mCRPC) whose disease has progressed after at least two prior therapies, the company announced. Therapies that target the androgen receptor, such…
This post was originally published on this site Women in the European Union with BRCA-mutated advanced ovarian cancer can now receive Lynparza (olaparib) as a first-line maintenance treatment, AstraZeneca and Merck (known as MSD outside the U.S. and Canada) announced. The European Commission’s decision follows a positive recommendation from the Committee for Medicinal Products for Human Use…
This post was originally published on this site CT103A, a fully-human anti-B-cell mature antigen (BCMA) CAR T-cell therapy, leads to strong anti-cancer responses in patients with relapsed or refractory multiple myeloma, including those who relapsed after receiving prior CAR T-cell therapy, data from a trial shows. The findings were presented in a poster, titled “Clinical…
This post was originally published on this site TRQ-1501, an experimental immune cell cancer therapy developed by Torque, was granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of certain hard-to-treat solid tumors and lymphomas. The designation is given to therapies that show potential to treat serious health conditions,…
This post was originally published on this site A combination of endocrine therapy and the targeted therapy Kisqali (ribociclib) is more effective than endocrine therapy alone at prolonging the survival of premenopausal women who have metastatic hormone receptor-positive breast cancer, a Phase 3 clinical trial suggests. Findings from the MONALEESA-7 trial (NCT02278120) were presented during…
This post was originally published on this site A vaccine produced using virus-like particles was able to improve cognitive functioning and reduce the accumulation of tau protein aggregates — a hallmark of Alzheimer’s disease — in a mouse model of the disease, a study shows. The study, “Qß Virus-like particle-based vaccine induces robust immunity and…
This post was originally published on this site Forty Seven and Acerta Pharma are collaborating to test a triple combination of the investigational 5F9 plus Rituxan (rituximab) and Calquence (acalabrutinib) in patients with diffuse large B-cell lymphoma (DLBCL). The partnership builds on prior Phase 1b data that showed a combination of Forty Seven’s 5F9 and Rituxan was safe and…
